The peril of biotech investing: ALS drug maker's phase 3 confirmation trial failed. https://finance.yahoo.com/m/b15fb91a-1e90-3259-844e-cfdb256344de/amylyx-stock-wipes-out-nearly.html
Often it happened the other way too when one received FDA approval for its drug. This guy went up 5x in less than 6 months. If you bought options in AMLX & this, you still come out ahead because of convexity:
@ironchef, what ticker do you mean when you say "this guy"? The ticker is missing on the chart. Update: I think I found it https://finance.yahoo.com/quote/IOVA
Sorry to hear that. I dodged a bullet on this one. Was going to buy some options a few months prior to the phase 3 because I had high hope it would be positive but ultimately passed on it because this reminded me of the aducanumab situation in Alzheimer's. More tragic are the ALS patients, it is their only hope to slow down the disease and give them a little more time.
I use to take a friend to UCSF Forbes Norris ALS Center. He was given Ritulek. Fast forward 24 years and it’s still one of the few drugs to help for a little. ALS is so complicated, maybe Jensen can help break the mystery with AI?
A dear friend was diagnosed with ALS (bulbar onset) three years ago. Dr gave him 1-2 years. He took AMX0035 (now called Relyvrio) for a year and a half and is still alive. That was why I was bullish on AMLX. One of the reasons I passed was I thought the phase 3 trial approval was already priced in by the market.